As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Medication Treatment Study for Patients with Treatment-Resistant Depression

Clinical Trial Title: 
This is a placebo-controlled study of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing antidepressant therapy in the treatment of treatment-resistant depression.
Clinical Trial Protocol ID: 
17042003
Clinical Trial Investigator Name: 
John Zajecka, MD
Clinical Trial Protocol Description: 

To evaluate the effectiveness, safety and tolerability of brexpiprazole in combination with intranasal ketamine, compared to placebo, as a rapidly acting treatment for treatment-resistant depression.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between the ages of 18-65 years old.
  • Meet criteria for treatment-resistant depression and have been experiencing depression for at least the past 8 weeks.
  • Are willing and able to use birth control (if you are a female of childbearing potential).

You will be excluded from the study if any of the following criteria apply to you:

  • Have certain other psychiatric or unstable medical illness, including bipolar disorder.
  • Test positive for drugs of abuse or alcohol at the time of screening.
  • Have had prior treatment with vagus nerve stimulation (VNS).
  • Are pregnant or breastfeeding.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Mental Health Disorders
Contact Phone: 
(312) 942-6597
Contact Name: 
Linda Skaggs